Prefer Glenmark, Jubilant Life and Aurobindo Pharma in midcap space: Ajay Bodke, Prabhudas Lilladher

In an interview with ET Now, Ajay Bodke, Prabhudas Lilladher, shares his views on markets. Excerpts:

ET Now: What is your opinion on names like Wockhardt, do they make for a good buy right now?

Ajay Bodke: Our preference remains with companies like Glenmark Pharmaceuticals, Jubilant Life Sciences and Aurobindo Pharma. These are the three names in the midcap space that we prefer and in case of large cap space, our preference remains with the Sun because we believe that most of the negatives have gotten priced in after the large one-time hit that the company took in the first quarter and as and when the Halol plant approval comes in, there is a very strong case for re-rating for Sun Pharmaceuticals. So these are the four stocks that we would advocate investors to look at with the medium term perspective in pharmaceuticals.